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Heart disease is the most frequent cause of death in the
western world [1-4]. Among the various manifestations of
this, sudden cardiac death is especially dramatic as are its
social and economic repercussions [5].
The term sudden death has been used in a variety of ways
by epidemiologists, clinicians and forensic pathologists.
There is no consensus regarding the precise definition of
sudden in terms of the time that must elapse from the onset of
symptoms to death. From a clinical point of view, sudden
death is generally considered to be attributable to natural
causes (excluding therefore accidents, suicide, poisoning,
etc.) and appears within an hour of the onset of symptoms. In
more than 90% of cases sudden death is caused by arrhyth-
mias and is characterized by loss of consciousness and ab-
sence of an arterial pulse, without prior circulatory collapse;
whereas sudden death due to heart failure involves progres-
sive failure and leads to circulatory collapse before cardiac
arrest occurs. If the patient is found dead, death is consid-
ered sudden if the subject was seen alive and well in the pre-
ceding 24 hours [6].
Epidemiology
According to a study by the WHO, the annual incidence of
sudden death in industrialized countries ranges from 19 to
159 cases per 100,000 males and from 35 to 64 per 100,000
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Abstract
Sudden death is a frequent event whose causes may not be
anticipated, but often has a cardiac origin. Sudden cardiac
death is the final consequence of many pathophysiological
mechanisms which have caused acute or chronic arrhyth-
mogenic disease. Single or multifactorial triggering factors
may interact with the arrhythmogenic substrate to lead to
lethal arrhythmias. Stratifying populations according to risk
is feasible, but the immediate priority is prevention of trigger-
ing and disease-promoting factors.
ICD therapy is the best treatment for most survivors of
sudden cardiac death. Drug therapy, catheter ablation, anti-
tachycardia surgery or heart transplant are only first-choice
treatments for very few patients. Choosing the best therapy
is an individual decision based on the patient’s clinical pic-
ture, the type of arrhythmia seen and hospital experience in
the various techniques.
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Resum
La mort sobtada representa un problema clínic per resoldre
que succeeix amb molta freqüència. En un elevat per-
centatge de casos, l’origen es cardíac. La mort sobtada
d’origen cardíac es la conseqüència final de múltiples
mecanismes fisiopatològics possibles, que promouen un
substrat arritmogènic de manera aguda o crònica. El desen-
volupament d’un o múltiples factors desencadenants pot in-
teractuar amb el substrat arritmogènic i facilitar l’arítmia final
amb característiques letals. A pesar de que l’estratificació
de risc de les poblacions es factible, la prevenció dels
mecanismes desencadenants i promotors de malalties es la
mesura més necessària i correcta.
El tractament amb el cardioversor-desfibril.lador im-
plantable (ICD) és el més segur per la gran majoria de per-
sones en les que s’ha pogut interrompre la mort sobtada
cardíaca. Només en un petit subgrup de pacients molt se-
leccionats, la teràpia amb fàrmacs, l’ablació transcateter, la
cirurgia antitaquicàrdica o el trasplantament de cor poden
ésser considerades com el tractament electiu. La decisió del
millor tractament per cada pacient cal considerar-la de for-
ma individualitzada, tenint en compte les seves caracterís-
tiques, el tipus d’arítmia que ha sofert el pacient i la pròpia
experiència de cada hospital en un tècnica determinada.
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females. Thus, it represents between 10 and 32% of all nat-
ural deaths, depending on the time that elapses from the on-
set of symptoms to death, making it the most common form
of fatal cardiac disease. About 50% of patients with is-
chemic heart disease die suddenly [1-8].
Sudden death shows a clear circadian rhythm, occurring
most frequently between 7 am and 11 am. This concurs with
the higher incidence between these times of various mani-
festations of ischemic heart disease (infarction, coronary
spasm, QTc variability, etc). As regards age, there are two
peaks in the incidence of sudden death. The first peak is
from birth to 6 months of life (infantile sudden death syn-
drome); the second peak occurs from 45 to 75 years and is
characterized by an increasingly greater frequency of is-
chemic heart disease after the age of 40 [6]. A multivariant
analysis carried out on the Framingham study, including all
coronary risk factors, showed that age, systolic pressure,
cigarrette consumption, and relative body weight are all risk
factors that are independently related to the incidence of
sudden death. In females, besides age, only choles-
terolemia and vital capacity were associated independently
with increased risk of sudden death.
Pathophysiology
The pathophysiology of sudden death needs to must be
viewed as a multifactorial problem that is inseparable from
associated diseases and that includes the precursors of
sudden death, the final step responsible for sudden death
as well as markers and triggering mechanisms of this event
[9-15].
Associated diseases
In about 90% of cases, sudden death occurs in persons with
heart disease. Most heart diseases may be associated with
sudden death (Table I), as we outline below:
Ischemic Heart Disease
Although sudden death occurs in all forms of heart disease,
in the west, ischemic heart disease is the most commonly
occurring associated disease [1-5]. Several mechanisms
can produce potentially fatal arrhythmias in patients with is-
chemic heart disease and it is often difficult to define the
precise mechanism of a given episode [9,10,16-19]. At one
extreme is the patient without a prior infarction who has an
acute occlusion of a major epicardial coronary artery and
develops ventricular fibrillation during the immediate phase
of acute infarction [7,20-22]. This patient illustrates the role
of acute severe transmural and persistent ischemia. At the
other end of the spectrum lies the patient with a history of
one or more previous myocardial infarctions, in whom
postinfarction scarring has provided the anatomic substrate
for a rapid reentrant ventricular tachycardia, triggering ven-
tricular fibrillation, with a resultant hemodynamic collapse
and sudden death; new ischemia does not necessarily have
to be present [10,17,23-26]. The majority of sudden death
victims with ischemic heart disease belong to these two
groups. In these patients sudden death is usually produced
by a complex interaction between several trigger-types – au-
tonomic nervous system dysfunction, electrolyte imbalance,
or drug toxicity among others – and the presence of different
interactions between electrical instability, residual ischemia
and left ventricular dysfunction (Figure 1) [10,27].
Autopsy and clinical studies differ in their findings of coro-
nary thrombi and the evidence of new ischemia in sudden
death patients. Evidence of coronary artery thrombi is re-
ported in between 20% and 50% of sudden death victims.
However, only about 25% of patients resuscitated from an
out-of-hospital cardiac arrest will develop new Q-wave my-
ocardial infarctions. While there may be persistent repolar-
ization abnormalities and enzymatic evidence of necrosis in
another 25% of patients, these changes are not specific for a
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Ischemic heart disease
Cardiomyopathies
Idiopathic dilated
Hypertrophic
Arrhythmogenic ventricular dysplasia
Valvular heart disease
Electrophysiologic abnormalities
Pre-excitation syndromes
Long-QT syndrome
Conduction system abnormalities
Brugada syndrome
Congenital cardiac abnormalities (e.g. abnormal coronary
origin)
Other cardiovascular diseases (e.g. pulmonary embolism,
dissecting aneurysm of the aorta)
Sudden death without apparent structural heart disease
Noncardiac diseases (e.g. massive gastrointestinal bleeding,
cerebral hemorrhage)
Sudden infant death syndrome
Table 1. Principal causes of sudden death *
* Heart failure is frequently present
Figure 1. Cascade of factors leading to ventricular fibrillation (VF).
ANS = autonomic nervous system, EI = Electrical instability, LVD =
left ventricular dysfunction, VT = ventricular tachycardia, R/T = R-
on-T phenomenon, SVT = supraventricular tachyarrhythmias.
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new infarction and may be caused by prolonged hipoten-
sion during a primary arrhythmia. There is also evidence
suggesting a contributing role for acute ischemia without
any signs or symptoms of infarction [9,10,21,22,27].
Coronary spasm and other diseases of the coronary arter-
ies not due to atherosclerosis, such as an abnormal left
coronary origin, may give rise to either myocardial infarction
with late ventricular tachycardia or to arrhythmias mediated
by acute intermitent ischemia and sudden death [6,7,27,28].
Cardiomyopathies
Idiopathic dilated cardiomyopathy is the primary cardiac di-
agnosis in 5-10% of resuscitated cardiac arrest victims.
Sudden death accounts for about a half of all deaths in pa-
tients with this diagnosis. Sudden death often occurs rela-
tively late in the course of dilated cardiomyopathy, after he-
modynamic symptoms have been present for some time.
Even with well-documented clinical episodes of ventricular
tachycardia or fibrillation, similar arrhythmias are frequently
not inducible at the time of electrophysiologic study [29,30].
In patients with dilated cardiomyopathy and very advanced
heart failure, bradiarrhythmia, rather than tachyarrhythmia,
is the final event that leads to sudden death.
In hypertrophic cardiomyopathy, sudden death often oc-
curs in young adults who usually have had no prior cardiac
symptoms. Polymorphic ventricular tachycardia or primary
ventricular fibrillation appear to be the initial arrhythmia at
the time of cardiac arrest. Patients with hypertrophic car-
diomyopathy are also at risk from AV block and the severe
hemodynamic compromise that may produce a cardiovas-
cular collapse can occur during any rapid supraventricular
tachycardia in these patients. In young athletes under 35,
sudden death occurs fundamentally in patients with car-
diomyopathy, usually, but not exclusively, of the hyper-
trophic variety. In contrast, sudden death in athletes over 35
is due to ischemic heart disease in 80% of victims [31,32].
Patients with arrhythmogenic right ventricular dysplasia
may also account for a small number of cases of cardiac ar-
rest and sudden death usually in young adults. The ventricu-
lar tachycardia that these patients typically present exhibits
a left bundle branch block on the ECG, and a QRS pattern
with negative T waves in the right precordial leads is usually
seen aurius sinus rhythm [33,34].
Valvular Heart Diseases
In mitral valve prolapse symptomatic atrial and ventricular
arrhythmias are common but truly life-threatening arrhyth-
mias are extraordinarily rare, except in the presence of cer-
tain complicating conditions such as long QT, electrolyte im-
balance, or drug toxicity.
In young adults with congenital aortic stenoses sudden
death is usually related to exertion probably due to sudden
changes in either ventricular filling or aortic obstruction with
a secondary arrhythmia. In the acquired forms of valvular
heart disease, sudden death is usually a late occurrence
seen in patients with advanced heart failure. Martínez-Rubio
et al. demonstrated that any patient with valvular heart dis-
ease who presents with sustained ventricular tachyarrhyth-
mias or syncope has to be considered as a very high risk pa-
tient because recurrence of sustained ventricular tach-
yarrhythmias or sudden death rate are high despite therapy
[35]. In addition, the data provided by these authors suggest
that such patients should be treated with implantable defib-
rillators while the mechanism of arrhythmias in them is par-
ticularly complex (multifactorial) [35].
Electrophysiological abnormalities
Supraventricular arrhythmias, if associated with very rapid
ventricular rates, may cause hemodynamic collapse and de-
generate to ventricular fibrillation. Atrial fibrillation with rapid
conduction over an accessory pathway in a patient with
Wolff-Parkinson-White syndrome is the supraventricular ar-
rhythmia most frequently associated with sudden death [36].
Prolongued QT syndrome, leading to irregular repolariza-
tion, facilitates the appearance of malignant ventricular ar-
rhythmias, usually ‘torsade de pointes’ leading to ventricular
fibrillation. This phenomenon often occurs against a back-
ground of physical or mental stress [37].
Primary bradiarrhythmias may also be associated with
sudden death [38]. In congenital complete heart block, the
escape rhythm may deteriorate over time, with ventricular ar-
rhythmias appearing as the patients bradicardia becomes
more and more inappropiate. Rare cases of malignant vagal
arrhythmias may also cause sudden death .
Idiopathic Ventricular fibrillation
In the absence of heart disease or other known casual fac-
tors, sudden death is exceptional. Idiopathic ventricular fib-
rillation represents about 1% of all cases of resuscitated out-
of-hospital cardiac arrest. Many retrospective studies with a
small number of patients confirm an unfavorable prognosis
for these patients. The recurrence of ventricular fibrillation is
oberved in 33% of patients not treated in the appropriate
manner, which would seem to be with an implantable defib-
rillator [39].
Precursors of sudden death
Cardiac sudden death occurs as a result of cardiac arrest
due usually to ventricular fibrillation (VF) or more rarely to
malignant bradiarrhythmias [38]. In both cases, a series of
precursors may be identified before sudden death appears
[9,18,24,40-43]. These include triggering mechanisms act-
ing on a vulnerable myocardium to precipitate the appear-
ance of the final step that terminates in either VF or, less fre-
quently, cardiac arrest due to a malignant bradiarrhythmia
though usually secondary to electromechanical dissociation
in patients with severe heart failure.
Final step
Usually the final step leads to ventricular fibrillation. The se-
quence of events occurring in the final step that precipitate
ventricular fibrillation can be called the ‘ventricular fibrillation
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cascade’ (Figure 1). These include a final arrhythmia re-
sponsible for sudden death and the electrophysiological
events that often precede sudden death. Below we describe
the arrhythmias and events that constitute the final step in a
range of clinical settings:
Pre-hospital phase of acute myocardial infarction
In patients whose sudden death is related to an acute my-
ocardial infarction, records taken in mobile coronary units
showed that the most frequent final arrhythmia was primary
VF unpreceded by ventricular tachycardia (82%) (Figure
2A). In these patients, an R-on-T phenomenon was ob-
served in 70% of cases. Characteristically, an increased
heart rate, due to sympathetic overdrive, was seen before
the lethal arrhythmia in patients with sudden death related to
an acute myocardial infarction.
Ambulatory patients with out-of-hospital sudden death
We have published the results of a worldwide survey includ-
ing 233 cases of patients who have died while wearing a
Holter recorder [6,38]. The conclusions of this study are
(Figure 2B):
a) Sudden death occurs due to a ventricular tach-
yarrhythmia in 80% of cases and due a severe bradiar-
rhythmia in the remaining 20%.
b) VF initiates abruptly in 10% of the individuals, in the
rest it is triggered by classical sustained ventricular
tachycardia (VT) or less often a ‘torsade de pointe’
ventricular tachycardia. The sustained VT leading to
VF was often preceded by sinus tachycardia or a new
supraventricular tachyarrhythmia.
On the other hand, in the group of patients with VF,
only 12% of patients presented ischemic ST changes
prior to the final event. However, the incidence of is-
chemic ST alterations requires further study using
Holter instruments equipped with three leads or more,
and should include observations on disturbances in
the autonomic nervous system such as heart rate vari-
ability.
c) In patients who died suddenly from bradiarrhythmia,
the cause was more often sinus depression than atri-
oventricular block, and the incidence of previous ST
changes was surprisingly high (>80%).
Patients with congestive heart failure
In patients with end-stage heart failure, Luu et al. [8] have
demonstrated that the incidence of ventricular tachyarrhyth-
mias as the final arrhythmia is much lower (40%) than the in-
cidence obtained in ambulatory patients in our series (ap-
proximately 80%). Interestingly, all patients who died of
VT/VF had a previous myocardial infarction, but previous
myocardial infarction was present in fewer than half of the
cases of the bradiarrhythmia/electromechanical dissocia-
tion group (Figure 2C). This finding, and hyponatremia in
the latter group, were the only two parameters that differen-
tiated between the bradiarrhythmia and tachyarhythmia
groups.
Electrophysiological disorders
In patients with Wolff-Parkinson-White syndrome who die
suddenly it has been shown that the final trigger of VF lead-
ing to sudden death is a supraventricular tachyarrhythmia,
usually atrial fibrillation with a very rapid ventricular rate
[36].
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Figure 2. In 2A we can see the proportions of final events in patients
with ventricular fibrillation during the acute phase of myocardial in-
farction (modified from reference 2). 2B shows the causes of ambu-
latory sudden death recorded by Holter electrocardiography (modi-
fied from reference 8). Finally, in 2C there is the incidence of final
events in patients with advanced heart failure who died suddenly
(modified from reference 6). AV = atrioventricular, Bradic. = brady-
cardia, EMD = electromechanical dissociation, IVR = idioventricular
rhythm, PVC = premature ventricular contractions, PVF = primary
ventricular fibrillation, R/T = R-on-T phenomenon, S-Bradic. = sinus
bradycardia, Torsade P = torsade de pointes, VF = ventricular fibril-
lation, VT = ventricular tachycardia
In patients with long QT syndrome, there is evidence that
adrenergic hyperactivity produced by physical and/or men-
tal stress may be responsible for triggering malignant ven-
tricular tachycardia of the torsades de pointes type [37]. In
addition, several drugs might influence the occurrence of
this electrophysiological disorder.
Patients with terminal noncardiac disease
Terminal cardiac activity has been described in adults who
died with no apparent indication of heart disease, generally
as a consequence of terminal malignancy present as bradiar-
rhythmia in 87% of patients and ventricular tachyarrhythmia in
17%. Agonal ST segment elevation was often observed.
Markers and Triggering Mechanisms of Sudden Death
The majority of patients who die suddenly present a vulnera-
ble myocardium. Below we will discuss the different markers
of this vulnerable myocardium and also the triggering fac-
tors, which acting on this vulnerable myocardium, may pre-
cipitate sudden death.
Postinfarction patients are the largest group, so we shall
focus initially on them. The risk of sudden death in these pa-
tients is related especially to the presence of electrical insta-
bility and to its interaction with left ventricular dysfunction
and residual ischemia. These three factors form the imagi-
nary triangle of risk of postinfarction complications (Figure
3). In figure 4 we can see various parameters of electrical in-
stability, ischemia and left ventricular dysfunction as mark-
ers that should alert us to the danger of a serious complica-
tion of myocardial infarction: malignant arrhythmias, new
coronary events, and overt heart failure directly or indirectly
increase the possibilities of triggering sudden death.
Various morphofunctional parameters (postinfarction
scar, left ventricular hypertrophy, reduced ejection fraction),
autonomic nervous system parameters (heart rate variability,
QT interval, baroreflex sensitivity), and clinical and electro-
cardiographic findings (previous history, ST depression on
surface ECG, number and nature of the ventricular arrhyth-
mias, presence of ventricular late potentials) may be consid-
ered as markers of electrical instability and, therefore, of my-
ocardial vulnerability to sudden death [9,18,24,26,42,44-46].
The markers of ischemia and left ventricular dysfunction are
also shown in figure 4.
The relationship between ischemia and sudden death de-
pends to a great extent on the duration and severity of is-
chemia. It is evident that persistent and severe transmural is-
chemia may induce sudden death in acute infarction.
However, in transitory transmural ischemia, such as
Prinzmetal’s angina and during PTCA, the relationship be-
tween ischemia and malignant ventricular arrhythmias is
less certain. During moderate subendocardial ischemia,
malignant ventricular arrhythmias are rare.
The five most important triggering factors which act on a
vulnerable myocardium are: 1) physical or mental stress; 2)
ionic or metabolic disorders; 3) acceleration of sinus rhythm
or appearance of a supraventricular arrhythmia or a pause;
4) the arrhythmogenic effect of certain drugs and 5) interac-
tion of electrical instability with ischemia and/or left ventricu-
lar dysfunction due to multiple causes [12,21,22,25,27,28,
43,47,48].
When sudden death occurs in patients with nonischemic
heart disease it is also conditioned by a vulnerable my-
ocardium and certain triggering factors. Heart failure, left
ventricular hypertrophy and electrical instability (ventricular
arrhythmias, autonomic nervous system dysfunction) are
usually the most important markers of vulnerable myocardi-
um, while other factors such as physical or mental stress,
ionic or metabolic disturbances, drug administration, etc,
may also act as triggers.
Identification of high risk candidates
Patients at greatest risk from sudden death (table 2) are
those who have previously experienced a malignant ventric-
ular arrhythmia (sustained VT or out-of-hospital cardiac ar-
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Malignant ventricular arrhythmia
Electrical
instability
LV dysfunction
Heart failure
Ischemia
New coronray event
Figure 3. Triangle of risk factors. The three angles are the main fac-
tors related to major complications in the postmyocardial infarction
patient. There is a strong interaction between these three factors. LV
= left ventricular.
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and platelet
aggregation
Figure 4. Triangle of risk factors with satellite triangles of markers. R
= risk, ANS = autonomic nervous system, PVC = premature ventric-
ular contraction, EI = electrical instability, LVD = left ventricular dys-
function.
rest). In patients without previous malignant ventricular ar-
rhythmias, the risk of sudden death is related to the pres-
ence of different markers, described earlier and related with
the evidence of advanced heart disease with left ventricular
dysfunction or even heart failure, and/or evidence of electri-
cal instability and/or residual ischemia when ischemic heart
disease is present.
Clinical data are very useful both for risk stratification of
patients who have presented severe arhythmias and for the
general population of postinfarction patients. Nonetheless,
complementary studies using different technologies need to
be undertaken to obtain more information about the triangle
of risk (Table 3).
Pronostic stratification in the thrombolytic era
There are some indications that the prognosis of patients
with or without fibrinolytic therapy following an acute my-
ocardial infarction differs. In a study by Farrell et al. in non-
thrombolyzed patients, the presence of ventricular prema-
ture beats (VPB) durign the Holter recording, decreased
heart rate variability (HRV), presence of late ventricular po-
tentials, the results of exercise testing and the value of ejec-
tion fraction discriminated those patients at high risk of fu-
ture arrhythmic events. However, in patients who received
thrombolytic therapy, only the diminished HRV discriminat-
ed between the two groups. Nevertheless, the incidence of
these risk markers (late ventricular potentials, low ejection
fraction, positive exercise testing, and decreased HRV) did
not differ in the two groups [49].
Other results concerning the incidence of certain markers
after thrombolysis are contradictory. Pedretti et al demon-
strated in post-myocardial infarction patients that thromboly-
sis significantly reduced the occurrence of arrhythmic
events [46]. On the contrary, the GISSI-2 study showed that
frequent premature ventricular beats, recorded by Holter
monitoring, remained even in the fibrinolytic era as an inde-
pendent risk factor of total and sudden death in the first 6
months following an acute myocardial infarction [26].
Prevention
The relatively low incidence of sudden death in Southern
Europe is related to the lower incidence of ischemic heart
disease, in comparison to Northern Europe and North
America. Efforts to reduce risk factors and to treat the acute
events as rapidly as possible are the best measures to re-
duce sudden death. The widespread use of recently devel-
oped therapies for acute events (thrombolysis, beat-block-
ers, aspirin, etc) and the global protection of the patient
during follow-up are mandatory [15,50-59]. Undoubtedly,
thrombolytic treatment has been crucial in decreasing mor-
tality, though in the acute phase of myocardial infarction it is
still relatively high. However, it should not be forgotten that a
global cardioprotective approach has been very effective in
reducing mortality particularly in the post-discharge phase
[11,15,55]. Hämaläinen et al. [11] evaluated effectiveness
before the thrombolytic era of a long-term multifactorial inter-
vention program to reduce sudden and cardiac death by
medication, cessation of smoking, physical exercise, diet,
psychosocial support and optimal medical care. The pa-
tients included in the intervention group had an incidence of
sudden death of 12.6% at 10 years as opposed to 23% in
the group that received no standarized intervention.
We should point out that all patients already presenting a
crisis of a malignant ventricular arrhythmia (sustained ven-
tricular tachycardia or ventricular fibrillation) must be treated
in a reference centre, because of the actual efficacy of non-
pharmacological therapies (implantable cardioverter-defib-
rillator, ablation, etc.).
Another group of patients to mention are those who have
not suffered a malignant arrhythmia, but who present high
risk markers. In post-myocardial infarction patients with the
following markers: low ejection fraction (<35%) + sponta-
neous non-sustained ventricular tachycardia on Holter mon-
itoring + inducible ventricular arrhythmia inducible during
the electrophysiologic study and non-suppressible due to
drug therapy, the MADIT Trial [45] has demonstrated that
the implantable cardioverter-defibrillator (ICD) is superior to
conventional drug therapy (including amiodarone) for pro-
tecting against sudden death. The ICD may also offer the so-
lution in the group of patients with cardiomyopathies at risk
of sudden death (Figure 5). In some other cases, such as
patients with WPW syndrome and paroxysmal tachyarrhyth-
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History of malignant ventricular arrhythmia (sustained ventricular
tachycardia or out-of-hospital cardiac arrest)
Heart disease with markers of a vulnerable myocardium for ma-
lignant ventricular arrhythmias (depressed contractility, is-
chemia, electrical instability)
Severe bradyarrhythmias
Table 2. Patients at high risk of sudden death
Clinical history and physical examination (syncope, angina, etc)
Surface ECG (Q-waves, ventricular enlargement, QT interval, ar-
rhythmias, etc.)
Exercise testing (ST-segment abnormalities, poor hemodynamic
response, arrhythmias, etc.)
Ambulatory Holter ECG (arrhythmias, ischemia, autonomic tone,
ventricular late potentials, etc.)
Electrophysiologic studies (induction of sustained ventricular
tachyarrhythmias, anomalous pathways, sinus node dysfunc-
tion, etc.)
Echocardiography-Doppler (ventricular function, aneurysm, is-
chemia, valvular dysfunction, etc.)
Nuclear studies (ventricular function, aneurysm, ischemia, etc.)
Cardiac angiography (coronary artery lesions, ventricular func-
tion, aneurysm, biopsy, valvular abnormalities, etc.)
Table 3. Methods to identify a high-risk patient
mias with electrophysiologic parameters of risk, radiofre-
quency catheter ablation may provide a definitive solution to
the problem. In long QT syndrome a good protection may be
achieved by blocking the adrenergic activation with beta-
blockers or, even better, with left estelectomy.
A large number of heart disease patients –currently more
than half of post-infarction patients have a low risk of sudden
death (without significant markers of electrical instability,
ventricular dysfunction and/or ischemia). In these cases, the
usual postinfarction treatment consists of acetilsalycilic
acid, beta-blockers and control of risk factors (tobacco, high
cholesterol levels, high blood pressure, etc). Recently, sev-
eral studies [56-67] have firmly established the value of sec-
ondary (e.g. 4S Trial) and primary (e.g. WSO Trial) coronary
prevention in reducing mortality by using inhibitors of the
HMG CoA reductase. The inhibitors of the angiotensin con-
verting enzyme have proven especially useful in patients
with myocardial infarction and left ventricular dysfunction
but are also recommended in all post-infarction patients af-
ter the ISIS-4 and GISSI-3 Trials. Amiodarone does not give
significant advantages against placebo (EMIAT Trial) or has
only been effective in some subsets of patients (CAMIAT
Trial). Other antiarrhythmic agents have shown a significant
increase in mortality (Class I agents –CAST Trial–; d Sotalol
–SWORD Trial-).
Thus, although prognosis has improved, sudden death
remains a frequent clinical occurrences and on unresolved
multifactorial problem which needs further research.
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